Why Smith & Nephew plc Is Attracting Interest From Stryker Corporation

Royston Wild explains why Smith & Nephew plc (LON: SN) could prove a shrewd purchase for Stryker Corporation (NYSE: SYK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in medical equipment manufacturer Smith & Nephew (LSE: SN) have exploded in pre-Christmas trading as speculation over a potential takeover by American group Stryker reaches fever pitch.

The London-based company is currently up around 8% at the time of writing, with shareholders cheering rumours that Smith & Nephew could be the latest healthcare specialist to be snapped up as M&A activity in the sector heats up. Here, I explain why the British company is attracting admiring gazes from across the Atlantic.

Imminent bid on the cards?

According to Bloomberg, surgical implant provider Stryker is readying a bid to acquire Smith & Nephew, a move that could be launched in the coming weeks. The US business commented in May that it was not about to launch a takeover offer for Smith & Nephew, preventing it from readying an attempt until late November at the earliest in line with stock market rules.

The report cited one source who explained that Smith & Nephew could command a premium of up to 30% of its share price. And unlike Pfizer’s attempted acquisition of AstraZeneca earlier this year, Stryker’s rumoured bid is apparently not being fuelled by controversial tax inversion, illustrating the underlying value of the British firm.

Earnings on course to ignite

Indeed, Europe’s largest manufacturer of artificial limbs has a stellar history of generating year-on-year earnings growth, and City analysts expect the business to punch growth to the tune of 4% in 2014, a figure which accelerates to 12% in 2015.

In response to escalating pressure from government and private health plans concerning the cost of its artificial body parts, this summer Smith & Nephew launched its Syncera initiative in the US, a strategy which could cut costs by half as part of a slimmed-down service. It is estimated that the scheme addresses between 5% and 10% of the market, and could drive Smith & Nephew’s current US market share — which currently stands at around 11% — through the roof.

On top of this, the business is also engaged in extensive work behind the scenes to bulk up the bottom line. From engaging in a vast $120m cost-stripping exercise, to rolling out IT systems which assist decision making by measuring profits according to product and country, Smith & Nephew is gearing up to build a much more intelligent earnings-generating machine.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »